The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Assoc. Prof. Nicole Lamanna | ASH 2017 | DUO Trial: Based on phase III DUO trial, which CLL patients would most benefit from duvelisib therapy?

Jan 3, 2018
Share:

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Associate Professor Nicole Lamanna
Columbia University Medical Center, New York, US

Interview topic: Based on phase III DUO trial, which CLL patients would most benefit from duvelisib therapy?

Assoc. Prof. Nicole Lamanna | ASH 2017 | DUO Trial: Based on phase III DUO trial, which CLL patients would most benefit from duvelisib therapy?

Share: